|
시장보고서
상품코드
1808951
세계의 흑색종 치료제 시장 : 치료 유형별, 병기별, 투여 경로별, 유통 경로별, 최종 사용자별, 국가별, 지역별 산업 분석, 시장 규모, 시장 점유율, 예측(2025-2032년)Melanoma Therapeutics Market, By Therapy Type, By Disease Stage, By Route of Administration, By Distribution Channel, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032 |
||||||
흑색종 치료제 시장의 규모는 2024년에 67억 129만 달러로 평가되었으며 2025년부터 2032년까지 연평균 복합 성장률(CAGR) 10.50%로 확대될 전망입니다.
흑색종 치료제 시장은 피부암의 이환율 상승, 조기 진단에 대한 의식 증가, 면역요법과 표적 치료의 진보 등을 배경으로 강력한 성장을 이루고 있습니다. PD-1 억제제나 CTLA-4 억제제와 같은 체크포인트 억제제 수요가 왕성하고 생존율이 대폭 개선된 것이 시장의 성장으로 이어지고 있습니다. 그러나 높은 치료비와 부작용은 여전히 도전 과제로 남아 있습니다. 하지만 맞춤형 의료, 병용 요법, 신흥 시장에서의 헬스케어 지출 증가 등이 기회입니다. 규제당국의 지원과 진행중인 임상 시험은 기술 혁신을 더욱 자극합니다. 전반적으로, 시장은 급속히 진화하고 있으며, 미래의 혁신을 기대하고 있습니다.
흑색종 치료제 시장 - 시장 역학
세계적인 암 이환율 증가
흑색종의 세계적인 이환율 증가는 흑색종 치료제 시장의 성장을 가속하는 주요 요인입니다. 세계보건기구(WHO)에 따르면 자외선 노출 증가, 실내 태닝 습관, 오존층 파괴 등의 요인으로 피부암 발생률은 꾸준히 상승하고 있습니다. 2022년에는 세계에서 33만명의 신규 환자가 흑색종으로 진단되었고, 거의 6만명이 이 질병으로 사망하였습니다. 예를 들어, 호주와 미국과 같은 국가에서는 국민 1인당 흑색종 사례가 가장 많아 효과적인 치료에 대한 수요가 증가하고 있습니다. 이 동향으로 인해 건강 관리 시스템과 제약 회사는 조기 발견 도구 및 고급 치료에 투자하기 위해 노력하고 있습니다. 이에 따라 펨브롤리주맙(키트루다)이나 니볼루맙 등의 면역요법이 널리 채용되어 생존율의 대폭적인 개선을 나타내고 있습니다. 홍보 캠페인과 정기적인 피부 검사가 보편화됨에 따라 효율적인 타겟형 치료에 대한 요구가 계속 커지고 있습니다.
흑색종 치료제 시장 - 세분화 분석
세계의 흑색종 치료제 시장은 치료 유형, 병기, 투여 경로, 유통 채널, 최종 사용자, 지역에 따라 구분됩니다.
시장은 치료 유형에 따라 면역요법, 표적요법, 화학요법, 방사선요법, 보조요법, 병용요법의 6가지 범주로 분류됩니다. 면역요법은 특히 진행성 및 전이성 흑색종 사례에서 높은 효능과 생존율을 얻을 수 있기 때문에 최대 시장 점유율을 차지하고 있습니다. 예를 들어, 펨브롤리주맙은 임상 시험에서 종래의 화학요법에 비해 우수한 치료 성적을 보였으며, 많은 국가에서 제1선택치료로 승인되었습니다. 단일요법과 병용요법 모두에서 면역요법이 선호되는 것은 현재 흑색종 치료 프로토콜에서 면역요법이 중심적인 역할을 한다는 것을 뒷받침합니다.
시장은 최종 사용자별로 병원, 조사 및 학술 기관, 종양 클리닉의 세 가지 범주로 나뉩니다. 병원은 종합적인 인프라, 고급 진단 및 치료 시설의 가용성, 복잡한 흑색종 사례를 관리할 수 있는 집학적 팀의 존재로 부문을 리드하고 있습니다. 예를 들어, 마요클리닉(미국)이나 AIIMS(인도)와 같은 대형 병원에서는 흑색종 치료를 위해 펨브롤리주맙과 같은 면역요법의 투여와 수술 절제가 일상적으로 이루어지고 있습니다. 게다가 암과 관련된 입원 환자 수 증가와 종양학 인프라에 대한 정부 투자 증가가 이 분야의 시장에서의 우위성을 더욱 강화하고 있습니다.
흑색종 치료제 시장 - 지리적 인사이트
북미는 세계의 흑색종 치료제 시장에서 가장 큰 점유율을 차지하고 있으며, 주요 요인은 높은 인지도, 확립된 건강 관리 인프라 및 고급 치료의 조기 도입입니다. 미국암협회에 의하면, 미국에서는 매년 10만명 이상의 신규 환자가 보고되어 흑색종의 증례 수가 많은 지역이 되고 있습니다. 키트루다와 옵디보와 같은 FDA 승인 면역요법을 이용할 수 있으며, 강력한 환급 정책이 치료에 대한 접근과 환자 확보를 지원합니다. 유럽도 이에 이어 독일과 영국 등 국가들이 종양학 연구와 임상 시험에 많은 투자를 하고 있습니다. 한편 아시아태평양은 의료비 증가, 피부암 환자 증가, 호주 및 일본과 같은 국가에서의 표적 치료에 대한 액세스 증가로 인해 가장 빠른 성장이 예상되고 있습니다. 호주는 자외선 피폭량이 많기 때문에 흑색종의 이환율이 세계에서 가장 높아 공중 보건에 중요한 대처가 촉진되고 있습니다. 전반적으로, 지역의 성장은 질병 부담, 규제 상황, 치료 비용의 저렴성에 달려 있습니다.
흑색종 치료제 시장 - 경쟁 구도
흑색종 치료제 시장은 면역 요법 및 표적 치료 기술 혁신에 견인되어 경쟁이 심합니다. Merck & Co., Bristol-Myers Squibb, Novartis와 같은 주요 기업들은 키트루다와 옵디보와 같은 승인된 약물로 강력한 임상 결과를 보여 주며 우위를 차지하고 있습니다. Immunocore는 포도막 흑색종에 대한 획기적인 신약 KIMMTRAK에서 주목을 받았으며, Iovance Biotherapeutics는 최근 T세포 치료제 Amtagvi의 FDA 승인을 받았습니다. 예를 들어, 2024년 10월에는 영국을 거점으로 하는 MANIFEST라고 명명된 새로운 연구 컨소시엄이 출범하여 많은 암 환자가 면역요법에 반응하지 않는 이유를 조사했습니다. 900만 파운드의 정부 자금과 1,290만 파운드의 산업계 파트너로부터의 지원으로 이 컨소시엄은 4년간 6,000명의 환자의 종양 바이오마커와 면역 세포를 연구할 예정이며 유방암, 방광암, 신장암, 피부암을 대상으로 합니다. BioNTech 및 Replimune과 같은 신흥 생명 공학 회사는 새로운 치료를 적극적으로 진행하고 있습니다. 이러한 상황은 고도의 R&D, 규제 변화, 전략적 제휴에 의해 형성됩니다. 지속적인 R&D 노력은 치료 효과 개선, 부작용 감소, 현행 요법에 대한 내성 극복에 중점을 둡니다. 또한 학술 기관이나 생명 공학 기업과의 제휴로 임상 시험과 의약품의 승인이 가속화되고 있습니다. 이러한 역동적인 R&D 상황은 치료 파이프라인을 확장하고 환자의 요구를 충족시키는 데 매우 중요합니다.
목차
제1장 흑색종 치료제 시장 개요
- 조사 범위
- 시장 추정 연도
제2장 주요 요약
- 시장 분석
- 경쟁 인사이트
제3장 흑색종 치료제의 주요 시장 동향
- 시장 성장 촉진 요인
- 시장 성장 억제 요인
- 시장 기회
- 시장 전망 동향
제4장 흑색종 치료제 산업 조사
- PEST 분석
- Porter's Five Forces 분석
- 성장 전망 맵핑
- 규제 틀 분석
제5장 흑색종 치료제 시장 : 높아지는 지정학적 긴장의 영향
- COVID-19 팬데믹의 영향
- 러시아-우크라이나 전쟁의 영향
- 중동 분쟁의 영향
제6장 흑색종 치료제 시장 상황
- 흑색종 치료제 시장 점유율 분석(2024년)
- 주요 제조업체별 분석 데이터
- 기존 기업의 분석
- 신흥 기업의 분석
제7장 흑색종 치료제 시장 - 치료 유형별
- 개요
- 치료 유형별 부문 점유율 분석
- 면역요법
- 표적요법
- 화학요법
- 방사선 치료
- 보조요법
- 병용요법
제8장 흑색종 치료제 시장 - 병기별
- 개요
- 병기별 부문 점유율 분석
- 조기 흑색종(스테이지 0-II)
- 전이성 흑색종(스테이지 IV)
- 국소성 흑색종(스테이지 III)
- 재발성 흑색종
제9장 흑색종 치료제 시장 - 투여 경로별
- 개요
- 투여 경로별 부문 점유율 분석
- 경구
- 국소
- 주사제(정맥내, 병변내)
제10장 흑색종 치료제 시장 - 유통 채널별
- 개요
- 유통 채널별 부문 점유율 분석
- 병원 약국
- 온라인 약국
- 소매 약국
제11장 흑색종 치료제 시장 - 최종 사용자별
- 개요
- 최종 사용자별 부문 점유율 분석
- 병원
- 조사 및 학술 기관
- 종양학 클리닉
제12장 흑색종 치료제 시장 - 지역
- 소개
- 북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
- 유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 네덜란드
- 스웨덴
- 러시아
- 폴란드
- 기타
- 아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 중국
- 인도
- 일본
- 한국
- 호주
- 인도네시아
- 태국
- 필리핀
- 기타
- 라틴아메리카(LATAM)
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
- 중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타
제13장 주요 벤더 분석 - 흑색종 치료제 업계
- 경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
- 기업 프로파일
- Merck &Co., Inc.
- Eisai Co., Ltd.
- Bristol-Myers Squibb Company
- BioNTech SE
- Novartis AG
- Pfizer Inc.
- Amgen Inc.
- Iovance Biotherapeutics, Inc.
- F. Hoffmann-La Roche Ltd.
- Immunocore Holdings plc
- Others
제14장 애널리스트의 종합적 전망
CSM 25.09.25The melanoma therapeutics market size was valued at US$ 6,701.29 Million in 2024, expanding at a CAGR of 10.50% from 2025 to 2032.
The Melanoma Therapeutics Market is witnessing robust growth driven by rising incidence rates of skin cancer, increasing awareness about early diagnosis, and advancements in immunotherapy and targeted treatments. The market benefits from strong demand for checkpoint inhibitors like PD-1 and CTLA-4 blockers, which have significantly improved survival rates. However, high treatment costs and adverse side effects of therapies remain key challenges. Opportunities lie in personalized medicine, combination therapies, and increased healthcare spending across emerging markets. Regulatory support and ongoing clinical trials further stimulate innovation. Overall, the market is evolving rapidly with strong potential for future breakthroughs.
Melanoma Therapeutics Market- Market Dynamics
Increasing global incidence of cancer cases across the globe
The increasing global incidence of melanoma is a key driver propelling the growth of the melanoma therapeutics market. According to the World Health Organization (WHO), skin cancer rates have been steadily rising due to factors such as increased UV exposure, indoor tanning habits, and ozone layer depletion. In 2022, an estimated 330,000 new cases of melanoma were diagnosed worldwide. and almost 60,000 people died from the disease. For instance, countries like Australia and the United States report some of the highest melanoma cases per capita, leading to heightened demand for effective treatments. This trend has pushed healthcare systems and pharmaceutical companies to invest in early detection tools and advanced therapies. In response, immunotherapies like pembrolizumab (Keytruda) and nivolumab have been widely adopted, demonstrating significant improvement in survival rates. As awareness campaigns and routine skin checks become more common, the need for targeted and efficient treatments continues to expand.
Melanoma Therapeutics Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.50% over the forecast period (2025-2032)
Based on therapy type segmentation, Immunotherapy was predicted to show maximum market share in the year 2024
Based on Disease Stage segmentation, Early-stage Melanoma (Stage 0-II) was the leading Disease Stage in 2024
Based on distribution segmentation, Hospital Pharmacies was the leading distribution in 2024
Based on end user segmentation, Hospitals was the leading end user in 2024
On the basis of region, North America was the leading revenue generator in 2024
Melanoma Therapeutics Market- Segmentation Analysis:
The Global Melanoma Therapeutics Market is segmented on the basis of Therapy Type, Disease Stage, Route of Administration , Distribution Channel, End User, and Region.
The market is divided into six categories based on therapy type: Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Adjuvant Therapy, and Combination Therapies. Immunotherapy holds the largest market share due to its high efficacy and survival benefits, especially in advanced and metastatic melanoma cases. For example, pembrolizumab has shown superior outcomes in clinical trials compared to conventional chemotherapy, leading to its approval as a first-line treatment in many countries. The growing preference for immunotherapies in both monotherapy and combination regimens underscores their central role in current melanoma treatment protocols.
The market is divided into three categories based on end user: Hospitals, Research & Academic Institutes and Oncology Clinics. Hospitals lead due to their comprehensive infrastructure, availability of advanced diagnostic and treatment facilities, and the presence of multidisciplinary teams capable of managing complex melanoma cases. For instance, large hospitals like Mayo Clinic (USA) or AIIMS (India) routinely administer immunotherapies such as pembrolizumab or conduct surgical excisions for melanoma treatment. Moreover, the rising number of hospital admissions related to cancer, coupled with growing government investments in oncology infrastructure, further strengthens this segment's dominance in the market.
Melanoma Therapeutics Market- Geographical Insights
North America holds the largest share of the global melanoma therapeutics market, primarily driven by high awareness levels, well-established healthcare infrastructure, and early adoption of advanced therapies. The United States leads the region with a significant number of melanoma cases annually over 100,000 new diagnoses are reported each year according to the American Cancer Society. The availability of FDA-approved immunotherapies such as Keytruda and Opdivo, along with strong reimbursement policies, supports treatment accessibility and patient uptake. Europe follows closely, with countries like Germany and the UK investing heavily in oncology research and clinical trials. Meanwhile, the Asia-Pacific region is expected to witness the fastest growth due to increasing healthcare expenditure, rising skin cancer cases, and growing access to targeted therapies in countries like Australia and Japan. Australia's high UV exposure has led to one of the world's highest melanoma incidence rates, prompting significant public health initiatives. Overall, regional growth is influenced by disease burden, regulatory landscape, and treatment affordability.
Melanoma Therapeutics Market- Competitive Landscape:
The Melanoma Therapeutics Market is highly competitive, driven by innovation in immunotherapies and targeted treatments. Leading players such as Merck & Co., Bristol-Myers Squibb, and Novartis dominate with approved drugs like Keytruda and Opdivo showing strong clinical outcomes. Immunocore gained attention with its breakthrough drug KIMMTRAK for uveal melanoma, while Iovance Biotherapeutics recently received FDA approval for its T-cell therapy Amtagvi. For instance, in Oct 2024, A new UK-based research consortium named MANIFEST has been launched to investigate why many cancer patients respond poorly to immunotherapy. Backed by £9 million in government funding and £12.9 million from industry partners, the initiative will study tumor biomarkers and immune cells from 6,000 patients over four years. Targeting breast, bladder, kidney, and skin cancers. Emerging biotech firms like BioNTech and Replimune are actively advancing novel therapies. The landscape is shaped by intense R&D, regulatory shifts, and strategic collaborations. Continuous R&D efforts are focused on improving treatment efficacy, reducing side effects, and overcoming resistance to current therapies. Additionally, partnerships with academic institutions and biotech firms are accelerating clinical trials and drug approvals. This dynamic R&D landscape is crucial for expanding the therapeutic pipeline and meeting unmet patient needs.
Recent Developments:
In April 2025, Immunai and the Parker Institute for Cancer Immunotherapy have partnered to create the world's largest single-cell dataset from cancer patients receiving immunotherapy. This initiative, powered by data from PICI's RADIOHEAD cohort, aims to uncover immune response patterns using AI and multi-omic profiling. The collaboration will accelerate drug discovery and improve treatment precision for cancers like melanoma.
In May 2025, RyboDyn has expanded its strategic partnership with Moffitt Cancer Center to accelerate the development of immunotherapies targeting novel cancer-specific proteins from the dark proteome. Using its AI-driven RyboCypher(TM) platform, RyboDyn will validate Dark Targets(TM) across diverse tumors. This collaboration aims to enable scalable, tumor-specific therapies with broad clinical impact.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL MELANOMA THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Merck & Co., Inc.
- Eisai Co., Ltd.
- Bristol-Myers Squibb Company
- BioNTech SE
- Novartis AG
- Pfizer Inc.
- Amgen Inc.
- Iovance Biotherapeutics, Inc.
- F. Hoffmann-La Roche Ltd.
- Immunocore Holdings plc
- Others
GLOBAL MELANOMA THERAPEUTICS MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Radiation Therapy
- Adjuvant Therapy
- Combination Therapies
GLOBAL MELANOMA THERAPEUTICS MARKET, BY DISEASE STAGE- MARKET ANALYSIS, 2019 - 2032
- Early-stage Melanoma (Stage 0-II)
- Metastatic Melanoma (Stage IV)
- Regional Melanoma (Stage III)
- Recurrent Melanoma
GLOBAL MELANOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Oral
- Topical
- Injectable (Intravenous, Intralesional)
GLOBAL MELANOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
GLOBAL MELANOMA THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Research & Academic Institutes
- Oncology Clinics
GLOBAL MELANOMA THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Table of Contents
1. Melanoma Therapeutics Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Melanoma Therapeutics Market Snippet by Therapy Type
- 2.1.2. Melanoma Therapeutics Market Snippet by Disease Stage
- 2.1.3. Melanoma Therapeutics Market Snippet by Route of Administration
- 2.1.4. Melanoma Therapeutics Market Snippet by Distribution Channel
- 2.1.5. Melanoma Therapeutics Market Snippet by End User
- 2.1.6. Melanoma Therapeutics Market Snippet by Country
- 2.1.7. Melanoma Therapeutics Market Snippet by Region
- 2.2. Competitive Insights
3. Melanoma Therapeutics Key Market Trends
- 3.1. Melanoma Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Melanoma Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Melanoma Therapeutics Market Opportunities
- 3.4. Melanoma Therapeutics Market Future Trends
4. Melanoma Therapeutics Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Melanoma Therapeutics Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Melanoma Therapeutics Market Landscape
- 6.1. Melanoma Therapeutics Market Share Analysis, 2024
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Melanoma Therapeutics Market - By Therapy Type
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Therapy Type, 2024 & 2032 (%)
- 7.1.2. Immunotherapy
- 7.1.3. Targeted Therapy
- 7.1.4. Chemotherapy
- 7.1.5. Radiation Therapy
- 7.1.6. Adjuvant Therapy
- 7.1.7. Combination Therapies
8. Melanoma Therapeutics Market - By Disease Stage
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Disease Stage, 2024 & 2032 (%)
- 8.1.2. Early-stage Melanoma (Stage 0-II)
- 8.1.3. Metastatic Melanoma (Stage IV)
- 8.1.4. Regional Melanoma (Stage III)
- 8.1.5. Recurrent Melanoma
9. Melanoma Therapeutics Market - By Route of Administration
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Topical
- 9.1.4. Injectable (Intravenous, Intralesional)
10. Melanoma Therapeutics Market - By Distribution Channel
- 10.1. Overview
- 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
- 10.1.2. Hospital Pharmacies
- 10.1.3. Online Pharmacies
- 10.1.4. Retail Pharmacies
11. Melanoma Therapeutics Market - By End User
- 11.1. Overview
- 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
- 11.1.2. Hospitals
- 11.1.3. Research & Academic Institutes
- 11.1.4. Oncology Clinics
12. Melanoma Therapeutics Market- By Geography
- 12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
- 12.2. North America
- 12.2.1. Overview
- 12.2.2. Melanoma Therapeutics Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.9. U.S.
- 12.2.9.1. Overview
- 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.2.9.3. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.2.9.4. U.S. Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.2.9.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.9.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.10. Canada
- 12.2.10.1. Overview
- 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.2.10.3. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.2.10.4. Canada Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.2.10.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.10.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3. Europe
- 12.3.1. Overview
- 12.3.2. Melanoma Therapeutics Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.9. Germany
- 12.3.9.1. Overview
- 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.9.3. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.3.9.4. Germany Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.3.9.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.9.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.10. UK
- 12.3.10.1. Overview
- 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.10.3. UK Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.3.10.4. UK Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.3.10.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.10.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.11. France
- 12.3.11.1. Overview
- 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.11.3. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.3.11.4. France Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.12. Italy
- 12.3.12.1. Overview
- 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.12.3. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.3.12.4. Italy Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.3.12.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.12.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.13. Spain
- 12.3.13.1. Overview
- 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.13.3. Spain Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.3.13.4. Spain Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.3.13.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.13.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.14. The Netherlands
- 12.3.14.1. Overview
- 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.14.3. The Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.3.14.4. The Netherlands Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.3.14.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.14.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.15. Sweden
- 12.3.15.1. Overview
- 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.15.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.3.15.4. Sweden Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.3.15.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.16. Russia
- 12.3.16.1. Overview
- 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.16.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.3.16.4. Russia Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.3.16.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.16.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.17. Poland
- 12.3.17.1. Overview
- 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.17.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.3.17.4. Poland Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.3.17.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.17.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.18. Rest of Europe
- 12.3.18.1. Overview
- 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.18.3. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.3.18.4. Rest of the Europe Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.3.18.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.18.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Melanoma Therapeutics Key Manufacturers in Asia Pacific
- 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.4.5. APAC Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.9. China
- 12.4.9.1. Overview
- 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.9.3. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.4.9.4. China Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.10. India
- 12.4.10.1. Overview
- 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.10.3. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.4.10.4. India Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.4.10.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.10.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.11. Japan
- 12.4.11.1. Overview
- 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.11.3. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.4.11.4. Japan Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.4.11.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.11.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.12. South Korea
- 12.4.12.1. Overview
- 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.12.3. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.4.12.4. South Korea Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.4.12.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.12.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.13. Australia
- 12.4.13.1. Overview
- 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.13.3. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.4.13.4. Australia Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.4.13.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.13.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.14. Indonesia
- 12.4.14.1. Overview
- 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.14.3. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.4.14.4. Indonesia Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.15. Thailand
- 12.4.15.1. Overview
- 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.15.3. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.4.15.4. Thailand Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.4.15.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.15.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.16. Philippines
- 12.4.16.1. Overview
- 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.16.3. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.4.16.4. Philippines Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.4.16.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.16.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.17. Rest of APAC
- 12.4.17.1. Overview
- 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.17.3. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.4.17.4. Rest of APAC Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.4.17.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.17.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5. Latin America (LATAM)
- 12.5.1. Overview
- 12.5.2. Melanoma Therapeutics Key Manufacturers in Latin America
- 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.5.5. LATAM Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.9. Brazil
- 12.5.9.1. Overview
- 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.9.3. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.5.9.4. Brazil Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.5.9.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.9.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.10. Mexico
- 12.5.10.1. Overview
- 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.10.3. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.5.10.4. Mexico Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.5.10.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.10.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.11. Argentina
- 12.5.11.1. Overview
- 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.11.3. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.5.11.4. Argentina Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.5.11.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.11.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.12. Colombia
- 12.5.12.1. Overview
- 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.12.3. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.5.12.4. Colombia Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.5.12.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.12.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.13. Rest of LATAM
- 12.5.13.1. Overview
- 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.13.3. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.5.13.4. Rest of LATAM Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.5.13.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.13.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Melanoma Therapeutics Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.9. Saudi Arabia
- 12.6.9.1. Overview
- 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.9.3. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.6.9.4. Saudi Arabia Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.6.9.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.9.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.10. United Arab Emirates
- 12.6.10.1. Overview
- 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.10.3. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.6.10.4. United Arab Emirates Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.6.10.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.10.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.11. Israel
- 12.6.11.1. Overview
- 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.11.3. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.6.11.4. Israel Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.6.11.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.11.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.12. Turkey
- 12.6.12.1. Overview
- 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.12.3. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.6.12.4. Turkey Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.6.12.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.12.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.13. Algeria
- 12.6.13.1. Overview
- 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.13.3. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.6.13.4. Algeria Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.6.13.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.13.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.14. Egypt
- 12.6.14.1. Overview
- 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.14.3. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.6.14.4. Egypt Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.6.14.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.14.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.15. Rest of MEA
- 12.6.15.1. Overview
- 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.15.3. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.6.15.4. Rest of MEA Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
- 12.6.15.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.15.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- Melanoma Therapeutics Industry
- 13.1. Competitive Dashboard
- 13.1.1. Competitive Benchmarking
- 13.1.2. Competitive Positioning
- 13.2. Company Profiles
- 13.2.1. Merck & Co., Inc.
- 13.2.2. Eisai Co., Ltd.
- 13.2.3. Bristol-Myers Squibb Company
- 13.2.4. BioNTech SE
- 13.2.5. Novartis AG
- 13.2.6. Pfizer Inc.
- 13.2.7. Amgen Inc.
- 13.2.8. Iovance Biotherapeutics, Inc.
- 13.2.9. F. Hoffmann-La Roche Ltd.
- 13.2.10. Immunocore Holdings plc
- 13.2.11. Others
14. 360 Degree Analyst View
15. Appendix
- 15.1. Research Methodology
- 15.2. References
- 15.3. Abbreviations
- 15.4. Disclaimer
- 15.5. Contact Us
